# US 2022/0033485 A1 · Anti-igf-i receptor humanized antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033485 A1
- Document ID: US20220033485A1
- Status: Published application
- Kind: A1
- Application number: 17/299,383
- Filed: 2019-12-02
- Published: 2022-02-03
- Earliest claimed: 2018-12-03
- Assignees: Teijin Pharma Limited
- Applicants: Teijin Pharma Limited
- Inventors: Akira TANOKURA; Hirotsugu KATO; Hiroshi EGUCHI; Kenichiro TAKAGI; Satoshi YAMAMURA; Naoko NAMIKI; Daisuke ISHIKAWA; Hirofumi HIGUCHI; Tomoyo TAKEO; Masayo OHORI
- Web page: https://patentgrep.com/patent/US20220033485A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

## Claims

### Claim 1

An anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof comprising:
as a sequence of CDR-1 of the heavy chain variable region (CDR-H1), the amino acid sequence defined in SEQ ID NO:1, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:1 via substitution of one amino acid residue;
as a sequence of CDR-2 of the heavy chain variable region (CDR-H2), the amino acid sequence defined in SEQ ID NO:2, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:2 via substitution of one or two amino acid residues;
as a sequence of CDR-3 of the heavy chain variable region (CDR-H3), the amino acid sequence defined in SEQ ID NO:3, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:3 via substitution of one or two amino acid residues;
as a sequence of CDR-1 of the light chain variable region (CDR-L1), the amino acid sequence defined in SEQ ID NO:4, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:4 via substitution of one or two amino acid residues;
as a sequence of CDR-2 of the light chain variable region (CDR-L2), the amino acid sequence defined in SEQ ID NO:5, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:5 via substitution of one amino acid residue; and
as a sequence of CDR-3 of the light chain variable region (CDR-L3), the amino acid sequence defined in SEQ ID NO:6, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:6 via substitution of one or two amino acid residues;
wherein the antibody, fragment, or derivative thereof specifically binds to an extracellular domain of SEQ ID NO:14 (human IGF-I receptor).

### Claim 2 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, comprising:
as a sequence of a heavy-chain variable region, the amino acid sequence defined in SEQ ID NO:7, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:7 via substitution, deletion, or addition of one or several amino acid residues; and
as a sequence of a light-chain variable region, the amino acid sequence defined in SEQ ID NO:8, or an amino acid sequence derived from the amino acid sequence defined in SEQ ID NO:8 via substitution, deletion, or addition of one or several amino acid residues.

### Claim 3 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, comprising:
as a sequence of a heavy-chain variable region, the amino acid sequence defined in SEQ ID NO:7; and
as a sequence of a light-chain variable region, an amino acid sequence selected from SEQ ID NOs:8, 9, 10, 11, and 12.

### Claim 4 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, comprising:
as heavy- and light-chain constant regions, the constant regions of each class of human immunogloblin.

### Claim 5 (depends on 4)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 4, wherein the heavy-chain constant region is the heavy-chain constant region of human IgG class 4.

### Claim 6 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, which binds to an epitope comprising a peptide having an amino acid sequence corresponding to the amino acid residues Nos. 308 to 319 (ProSerGlyPheIleArgAsnGlySerGlnSerMet) of SEQ ID NO:14 (human IGF-I receptor) or a region in the vicinity thereof.

### Claim 7 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, which, when administered at a dosage sufficient to induce proliferation of cultured myoblasts derived from human or guinea pig, does not induce glucose uptake of the cultured cells.

### Claim 8 (depends on 1)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1, which, when administered to a vertebrate at a dosage sufficient to induce an increase in the muscle mass and/or the body length of the vertebrate, does not decrease the blood glucose level of the vertebrate.

### Claim 9 (depends on 8)

The anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 8, which, when administered to a vertebrate at a blood exposure level which is 10 times or more an effective dosage to induce an increase in the muscle mass and/or the body length of the vertebrate, does not decrease the blood glucose level of the vertebrate.

### Claim 10 (depends on 1)

A nucleic acid molecule consisting of a polynucleotide sequence encoding an anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1.

### Claim 11 (depends on 10)

A cloning vector or expression vector comprising at least one nucleic acid molecule according to claim 10.

### Claim 12 (depends on 11)

A recombinant cell derived by introducing a vector according to claim 11 into a host cell.

### Claim 13 (depends on 12)

A process of producing an anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof, comprising:
culturing a recombinant cell according to claim 12; and
purifying an anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof produced by the recombinant cell.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising, as an active ingredient, an anti-IGF-I receptor humanized antibody or its fragment or a derivative thereof according to claim 1.

### Claim 15 (depends on 14)

A method for treating muscle atrophic disease or dwarfism, said method comprising administering, to a subject in need thereof, the composition of claim 14.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the muscle atrophic disease is disuse muscle atrophy, sarcopenia, or cachexia.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the dwarfism is Laron-type dwarfism or growth-hormone resistant dwarfism.

### Claim 18 (depends on 10)

A pharmaceutical composition comprising, as an active ingredient, the nucleic acid molecule according to claim 10.

### Claim 19 (depends on 11)

A pharmaceutical composition comprising, as an active ingredient, the vector according to claim 11.

### Claim 20 (depends on 12)

A pharmaceutical composition comprising, as an active ingredient, the recombinant cell according to claim 12.
